X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (38435) 38435
Book Chapter (107) 107
Newsletter (58) 58
Magazine Article (51) 51
Dissertation (22) 22
Book / eBook (20) 20
Publication (12) 12
Conference Proceeding (9) 9
Reference (7) 7
Newspaper Article (6) 6
Web Resource (5) 5
Book Review (4) 4
Streaming Video (4) 4
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22195) 22195
index medicus (17060) 17060
mycobacterium tuberculosis - drug effects (13726) 13726
tuberculosis (13539) 13539
animals (8739) 8739
female (8576) 8576
microbiology (8443) 8443
male (8177) 8177
mycobacterium-tuberculosis (7689) 7689
antitubercular agents - pharmacology (6999) 6999
infectious diseases (6841) 6841
microbial sensitivity tests (6492) 6492
mycobacterium tuberculosis (6261) 6261
adult (5916) 5916
immunology (5395) 5395
middle aged (4912) 4912
mice (4837) 4837
mycobacterium tuberculosis - genetics (4359) 4359
antitubercular agents - therapeutic use (4286) 4286
pharmacology & pharmacy (4113) 4113
mycobacterium tuberculosis - isolation & purification (3924) 3924
research article (3337) 3337
drug resistance (3195) 3195
anti-bacterial agents - pharmacology (3119) 3119
infection (3080) 3080
research (3063) 3063
aged (2905) 2905
tuberculosis - drug therapy (2858) 2858
infections (2835) 2835
drug resistance, microbial (2819) 2819
biochemistry & molecular biology (2813) 2813
analysis (2750) 2750
bacteria (2677) 2677
respiratory system (2590) 2590
tuberculosis, pulmonary - drug therapy (2584) 2584
health aspects (2575) 2575
tuberculosis - microbiology (2573) 2573
adolescent (2476) 2476
diagnosis (2455) 2455
medicine (2441) 2441
chemistry, medicinal (2360) 2360
pulmonary tuberculosis (2339) 2339
mycobacterium - drug effects (2314) 2314
mutation (2235) 2235
tuberculosis, pulmonary - microbiology (2145) 2145
rifampin - pharmacology (2143) 2143
isoniazid - pharmacology (2097) 2097
bacterial proteins - genetics (2062) 2062
multidisciplinary sciences (1998) 1998
treatment outcome (1920) 1920
macrophages (1894) 1894
mycobacterium tuberculosis - immunology (1883) 1883
drug resistance, bacterial (1869) 1869
risk factors (1847) 1847
tuberculosis, multidrug-resistant - drug therapy (1826) 1826
proteins (1809) 1809
antitubercular agents (1781) 1781
bacterial proteins - metabolism (1679) 1679
young adult (1638) 1638
time factors (1637) 1637
escherichia-coli (1630) 1630
antitubercular agents - chemistry (1626) 1626
antibiotics (1623) 1623
child (1615) 1615
identification (1615) 1615
tuberculosis, multidrug-resistant - microbiology (1615) 1615
resistance (1612) 1612
structure-activity relationship (1612) 1612
drug resistance in microorganisms (1607) 1607
epidemiology (1597) 1597
drug therapy, combination (1581) 1581
care and treatment (1578) 1578
drug therapy (1557) 1557
sputum - microbiology (1541) 1541
mycobacterium (1523) 1523
rifampin (1516) 1516
science (1516) 1516
mycobacterium tuberculosis - growth & development (1491) 1491
mycobacterium tuberculosis - metabolism (1483) 1483
mycobacterium tuberculosis - enzymology (1480) 1480
mycobacteria (1476) 1476
physiological aspects (1438) 1438
genetic aspects (1437) 1437
disease (1416) 1416
drugs (1346) 1346
virulence (1342) 1342
anti-bacterial agents - therapeutic use (1322) 1322
cell biology (1314) 1314
in-vitro (1293) 1293
susceptibility (1289) 1289
retrospective studies (1280) 1280
hiv (1279) 1279
expression (1277) 1277
tuberculosis - epidemiology (1268) 1268
biology (1266) 1266
tuberculosis - immunology (1253) 1253
infectious disease (1249) 1249
mycobacterium tuberculosis - pathogenicity (1244) 1244
prevalence (1235) 1235
molecular structure (1234) 1234
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (8) 8
Online Resources - Online (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
West Park Healthcare Centre - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (35500) 35500
Japanese (882) 882
Russian (801) 801
German (519) 519
French (503) 503
Spanish (296) 296
Chinese (264) 264
Italian (236) 236
Polish (175) 175
Romanian (67) 67
Portuguese (60) 60
Czech (53) 53
Turkish (47) 47
Ukrainian (36) 36
Croatian (24) 24
Dutch (24) 24
Danish (15) 15
Hungarian (15) 15
Swedish (14) 14
Korean (9) 9
Serbian (9) 9
Slovak (8) 8
Bulgarian (5) 5
Norwegian (5) 5
Finnish (4) 4
Hebrew (3) 3
Lithuanian (3) 3
Arabic (2) 2
Bosnian (2) 2
Greek (2) 2
Persian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS Pathogens, ISSN 1553-7366, 05/2015, Volume 11, Issue 5, p. e1004917
Pulmonary cavities, the hallmark of tuberculosis (TB), are characterized by high mycobacterial load and perpetuate the spread of M. tuberculosis. The mechanism... 
MYCOBACTERIUM-TUBERCULOSIS | ACTIVATED PROTEIN-KINASE | MICROBIOLOGY | IN-VITRO | VIROLOGY | INTERFERON-GAMMA | INFECTION | EXTRACELLULAR TRAPS | NF-KAPPA-B | LUNG INFLAMMATION | T-CELLS | PARASITOLOGY | INNATE IMMUNITY | AMP-Activated Protein Kinases - metabolism | Tuberculosis, Pulmonary - metabolism | Respiratory Mucosa - drug effects | Humans | Mycobacterium tuberculosis - immunology | NF-kappa B - metabolism | Tuberculosis, Pulmonary - drug therapy | Host-Pathogen Interactions - drug effects | Mycobacterium tuberculosis - drug effects | Respiratory Mucosa - pathology | Proteolysis - drug effects | Protein Processing, Post-Translational - drug effects | Matrix Metalloproteinase 8 - metabolism | Respiratory Mucosa - immunology | Mycobacterium tuberculosis - physiology | Adult | Lung - metabolism | Phosphorylation - drug effects | Neutrophils - metabolism | Extracellular Matrix Proteins - metabolism | Neutrophil Infiltration - drug effects | Neutrophils - pathology | Lung - pathology | Immunity, Innate - drug effects | Neutrophils - enzymology | Cells, Cultured | Enzyme Inhibitors - pharmacology | Neutrophils - immunology | Tuberculosis, Pulmonary - pathology | Matrix Metalloproteinase 8 - chemistry | Tuberculosis, Pulmonary - immunology | Active Transport, Cell Nucleus - drug effects | Lung - drug effects | Respiratory Mucosa - metabolism | Sputum - enzymology | Lung - immunology | Cohort Studies | Proteins | Studies | Pathology | Tuberculosis | Biomedical research | Disease | Biopsy | Infections | Kinases | Metabolism | Experiments
Journal Article
Clinical & Experimental Immunology, ISSN 0009-9104, 07/2010, Volume 161, Issue 1, pp. 1 - 9
.... The use of some of these drugs has been linked to reactivation TB. In addition to blocking TNF-mediated immune responses, some anti-TNF drugs have been found... 
certolizumab | mycobacteria | etanercept | infliximab | adalimumab | golimumab | Golimumab | Etanercept | Infliximab | Adalimumab | Certolizumab | Mycobacteria | BACILLUS-CALMETTE-GUERIN | INTRACELLULAR MYCOBACTERIUM-TUBERCULOSIS | ACTIVE RHEUMATOID-ARTHRITIS | IMMUNOLOGY | PHAGOSOME MATURATION ARREST | HOST-DEFENSE MECHANISM | REGULATORY T-CELLS | INFLIXIMAB INDUCES APOPTOSIS | FACTOR ANTAGONISTS | ANTI-TNF-ALPHA | CASPASE-DEPENDENT PATHWAY | Apoptosis - drug effects | Humans | Antibodies, Monoclonal - adverse effects | Mycobacterium tuberculosis - immunology | Autophagy - drug effects | Inflammation - complications | Immunity, Cellular - drug effects | Inflammation - drug therapy | T-Lymphocyte Subsets - drug effects | Immunoglobulin G - pharmacology | Dendritic Cells - drug effects | Immunosuppressive Agents - pharmacology | Autoimmune Diseases - drug therapy | Phagosomes - drug effects | Disease Susceptibility | Antibodies, Monoclonal - pharmacology | Autoimmune Diseases - complications | Immunoglobulin G - adverse effects | Tuberculosis - immunology | Animals | Receptors, Tumor Necrosis Factor | Lymphocyte Activation - drug effects | Tumor Necrosis Factor-alpha - physiology | Immunosuppressive Agents - adverse effects | Mice | Macrophage Activation - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Mycobacterium tuberculosis - growth & development | Rheumatoid factor | Tuberculosis | Bacterial infections | Rheumatoid arthritis | Biological response modifiers | T cells | Necrosis | Tumors | Interferon gamma | TNF inhibitors | Immune system | Review
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2012, Volume 109, Issue 27, pp. 10984 - 10989
Aminoglycosides are potent antibacterials, but therapy is compromised by substantial toxicity causing, in particular, irreversible hearing loss. Aminoglycoside... 
Deafness | Antibacterials | Antibiotics | Protein synthesis | Hair cells | Drug interactions | Ribosomes | Glycosides | Aminoglycosides | Inhibitory concentration 50 | Misreading | Antibiotic | Translation | Mycobacteria | antibiotic | SITE | TRANSLOCATION | ANTIBIOTICS | RNA | MULTIDISCIPLINARY SCIENCES | 30S RIBOSOMAL-SUBUNIT | TOXICITY | mycobacteria | INDUCED HEARING-LOSS | HAIR-CELLS | misreading | translation | RESISTANCE | deafness | SELECTIVITY | Humans | Nebramycin - toxicity | Bacteria - drug effects | Protein Biosynthesis - physiology | Ribosomes - metabolism | Gentamicins - toxicity | Drug Design | HEK293 Cells | Anti-Bacterial Agents - toxicity | Binding Sites - drug effects | Organ Culture Techniques | Rabbits | Guinea Pigs | Nebramycin - chemistry | Bacterial Infections - drug therapy | Ribosomes - chemistry | Deafness - physiopathology | Mitochondria - metabolism | Mitochondria - drug effects | Pseudomonas aeruginosa - drug effects | Nebramycin - analogs & derivatives | Mycobacterium - drug effects | Hair Cells, Auditory - drug effects | Animals | Reticulocytes - cytology | Aminoglycosides - toxicity | Ribosomes - drug effects | Protein Biosynthesis - drug effects | Mice | Mutagenesis - physiology | Staphylococcus aureus - drug effects | Deafness - chemically induced | Physiological aspects | Development and progression | Health aspects | Hearing loss | Biological Sciences
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 1/2013, Volume 207, Issue 1, pp. 18 - 29
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2012, Volume 7, Issue 10, p. e47542
Background: Mortality in the first months of antiretroviral therapy (ART) is a significant clinical problem in sub-Saharan Africa. To date, no post-mortem... 
AUTOPSY | RECONSTITUTION INFLAMMATORY SYNDROME | SUB-SAHARAN AFRICA | TUBERCULOSIS | MULTIDISCIPLINARY SCIENCES | HIV-POSITIVE PATIENTS | DISEASE | ADULTS | COHORT | EARLY MORTALITY | PATHOLOGY | Liver - virology | Tuberculosis, Pulmonary - microbiology | Liver - pathology | Kidney - pathology | Humans | Middle Aged | Male | Tuberculosis, Pulmonary - drug therapy | Bacterial Infections - virology | Liver - drug effects | Autopsy | HIV Infections - mortality | Lymph Nodes - drug effects | Bacterial Infections - microbiology | Bone Marrow - drug effects | Bone Marrow - virology | Kidney - drug effects | Bacterial Infections - drug therapy | HIV Infections - virology | Tuberculosis, Pulmonary - pathology | Tuberculosis, Pulmonary - mortality | Bacterial Infections - pathology | Lung - drug effects | Biopsy, Needle | Kidney - virology | Bacterial Infections - mortality | Mycobacterium tuberculosis - growth & development | Lymph Nodes - pathology | Mycobacterium tuberculosis - drug effects | Cause of Death | HIV - drug effects | Lung - virology | Immune Reconstitution Inflammatory Syndrome - virology | HIV Infections - pathology | Adult | Female | Skin - virology | Skin - pathology | Lung - pathology | South Africa - epidemiology | Lymph Nodes - virology | Immune Reconstitution Inflammatory Syndrome - mortality | HIV - growth & development | Antiretroviral Therapy, Highly Active | Immune Reconstitution Inflammatory Syndrome - pathology | Bone Marrow - pathology | Immune Reconstitution Inflammatory Syndrome - drug therapy | HIV Infections - drug therapy | Skin - drug effects | Tuberculosis, Pulmonary - virology | Antiviral agents | Bacterial infections | Mycobacterium tuberculosis | Dosage and administration | Diagnosis | Research | Drug therapy | Risk factors | Reproductive health | Health sciences | Therapy | Laboratories | Liver | Systematic review | Infections | Cerebrospinal fluid | Drug resistance | Lymph nodes | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Bone marrow | Bacteria | Ultrasound | Spleen | Autopsies | Kidneys | Internal medicine | Mortality | Immune reconstitution | Inflammation | Patients | Antiretroviral therapy | Medicine | Hospitals | Tuberculosis | Infectious diseases | Lungs | Biopsy | Death | Fatalities | Adults | Skin | Kidney transplantation | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2013, Volume 8, Issue 10, p. e78351
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 11/2009, Volume 180, Issue 9, pp. 896 - 902
Rationale: The optimal therapeutic regimen and duration of treatment for Mycobacterium abscessus lung disease is not well established. Objectives: To assess... 
Treatment outcome | Lung diseases | Mycobacterium abscessus | Atypical mycobacteria | lung diseases | DIAGNOSIS | INFECTIONS | NONTUBERCULOUS MYCOBACTERIA | CLARITHROMYCIN RESISTANCE | treatment outcome | CHELONAE | atypical mycobacteria | RAPIDLY GROWING MYCOBACTERIA | IN-VITRO | RESPIRATORY SYSTEM | MULTIDRUG-RESISTANT TUBERCULOSIS | SP-NOV | NODULAR BRONCHIECTASIS | CRITICAL CARE MEDICINE | Sputum - microbiology | Lung - microbiology | Cefoxitin - therapeutic use | Lung Diseases - microbiology | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Lung - diagnostic imaging | Lung Diseases - drug therapy | Anti-Bacterial Agents - therapeutic use | Sputum - drug effects | Liver - drug effects | Mycobacterium Infections, Nontuberculous - microbiology | Adult | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Drug Therapy, Combination | Neutropenia - chemically induced | Chemical and Drug Induced Liver Injury - etiology | Doxycycline - adverse effects | Ciprofloxacin - adverse effects | Nontuberculous Mycobacteria - drug effects | Clarithromycin - adverse effects | Doxycycline - therapeutic use | Ciprofloxacin - therapeutic use | Anti-Infective Agents - therapeutic use | Treatment Outcome | Clarithromycin - therapeutic use | Thrombocytopenia - chemically induced | Nontuberculous Mycobacteria - isolation & purification | Amikacin - adverse effects | Amikacin - therapeutic use | Lung - drug effects | Cefoxitin - adverse effects | Mycobacterium Infections, Nontuberculous - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 04/2014, Volume 57, Issue 7, pp. 3126 - 3139
Journal Article
Nature, ISSN 0028-0836, 01/2015, Volume 517, Issue 7535, pp. 455 - 459
... compounds (4-5). However, antimicrobial drug discovery is uniquely difficult (6), primarily due to poor penetration of compounds into bacterial cells. Natural products... 
IN-VITRO | STREPTOCOCCUS-PNEUMONIAE | PEPTIDOGLYCAN PRECURSOR | MULTIDISCIPLINARY SCIENCES | ESCHERICHIA-COLI | PRECURSOR LIPID II | ENTEROCOCCUS-FAECIUM | STAPHYLOCOCCUS-AUREUS | VANCOMYCIN-RESISTANCE | CELL-WALL BIOSYNTHESIS | DISCOVERY | Molecular Sequence Data | Biological Products - pharmacology | Depsipeptides - pharmacology | Drug Resistance, Microbial - genetics | Betaproteobacteria - chemistry | Mycobacterium tuberculosis - drug effects | Microbial Sensitivity Tests | Teichoic Acids - biosynthesis | Cell Wall - drug effects | Mycobacterium tuberculosis - cytology | Time Factors | Anti-Bacterial Agents - chemistry | Female | Staphylococcal Infections - microbiology | Depsipeptides - chemistry | Disease Models, Animal | Multigene Family - genetics | Staphylococcus aureus - genetics | Staphylococcal Infections - drug therapy | Microbial Viability - drug effects | Depsipeptides - isolation & purification | Depsipeptides - biosynthesis | Anti-Bacterial Agents - isolation & purification | Cell Wall - chemistry | Biological Products - isolation & purification | Betaproteobacteria - genetics | Staphylococcus aureus - chemistry | Peptidoglycan - biosynthesis | Biological Products - chemistry | Animals | Cell Wall - metabolism | Staphylococcus aureus - cytology | Anti-Bacterial Agents - biosynthesis | Anti-Bacterial Agents - pharmacology | Mice | Staphylococcus aureus - drug effects | Mycobacterium tuberculosis - genetics | Drug resistance in microorganisms | Antibiotics | Health aspects | Analysis | Soil microbiology | Proteins | Enzymes | Microorganisms | Bacteria | Antimicrobial agents | Lipids | Biosynthesis | Drug resistance | Drug dosages | Bacteriology | Deoxyribonucleic acid--DNA
Journal Article